UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

The Journal of infectious diseases, 2018-04, Vol.217 (10), p.1616-1625

2018

Volltextzugriff (PDF)

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults

Clinical infectious diseases, 2020-05, Vol.70 (10), p.2073-2081

2020

Volltextzugriff (PDF)

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial

The journals of gerontology. Series A, Biological sciences and medical sciences, 2019-07, Vol.74 (8), p.1217-1224

2019

Volltextzugriff (PDF)

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

Frontiers in immunology, 2017-08, Vol.8, p.943-943

2017

Volltextzugriff (PDF)

2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S746-S747

2018

Volltextzugriff (PDF)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

The Journal of infectious diseases, 2023-03, Vol.227 (6), p.761-772

2023

Volltextzugriff (PDF)

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

The New England journal of medicine, 2023-02, Vol.388 (7), p.595-608

2023

Volltextzugriff (PDF)

EFICÁCIA DE UMA VACINA DE PROTEÍNA F PRÉ-FUSÃO DO VÍRUS SINCICIAL RESPIRATÓRIO (RSVPREF3 OA) EM ADULTOS MAIS VELHOS COM CONDIÇÕES CARDIORRESPIRATÓRIAS COEXISTENTES

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.103095, Article 103095

2023

Volltextzugriff (PDF)

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

The Journal of infectious diseases, 2017-01, Vol.215 (1), p.24-33

2017

Volltextzugriff (PDF)

Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans

Vaccine, 2019-03, Vol.37 (14), p.2004-2015

2019

Volltextzugriff (PDF)

280-LB: Efficacy of a Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults with Preexisting Medical Conditions

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Clinical infectious diseases, 2024-01, Vol.78 (1), p.202-209

2024

Volltextzugriff (PDF)

Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial

Clinical immunology (Orlando, Fla.), 2016-08, Vol.169, p.16-27

2016

Volltextzugriff (PDF)

Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants

Human vaccines & immunotherapeutics, 2020-06, Vol.16 (6), p.1327-1337

2020

Volltextzugriff (PDF)

Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine

Clinical and Vaccine Immunology, 2014-03, Vol.21 (3), p.302-311

2014

Volltextzugriff (PDF)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S188-S189

2020

Volltextzugriff (PDF)

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S187-S188

2020

Volltextzugriff (PDF)

Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial

The Pediatric infectious disease journal, 2013-01, Vol.32 (1), p.62-71

2013

Volltextzugriff (PDF)

Persistence clinical studies: Can you believe what you see?

Human vaccines & immunotherapeutics, 2013-06, Vol.9 (6), p.1351-1357

2013

Volltextzugriff (PDF)

Hypnosis as adjunct therapy in conscious sedation for plastic surgery

Regional anesthesia, 1995-03, Vol.20 (2), p.145

1995

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(11)
Immunology
(11)
Infectious Diseases
(7)
Adult
(6)
Female
(6)
Microbiology
(6)
Respiratory Syncytial Virus
(6)
Vaccines
(6)
Male
(5)
Respiratory Syncytial Virus Infections - Prevention & Control
(5)
Young Adult
(5)
Adolescent
(4)
Antibodies, Viral
(4)
Respiratory Syncytial Virus Vaccines - Adverse Effects
(4)
Adjuvants, Immunologic - Administration & Dosage
(3)
Aged
(3)
Antibodies, Neutralizing
(3)
F Protein
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

EFICÁCIA DE UMA VACINA DE PROTEÍNA F PRÉ-FUSÃO DO VÍRUS SINCICIAL RESPIRATÓRIO (RSVPREF3 OA) EM ADULTOS MAIS VELHOS COM CONDIÇÕES CARDIORRESPIRATÓRIAS COEXISTENTES

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans

280-LB: Efficacy of a Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults with Preexisting Medical Conditions

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial

Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants

Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial

Persistence clinical studies: Can you believe what you see?

Hypnosis as adjunct therapy in conscious sedation for plastic surgery

Suchergebnisse filtern